Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Iovance Biotherapeutics (NASDAQ:IOVA) but has lowered the price target from $40 to $18.
September 18, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays maintains an Overweight rating on Iovance Biotherapeutics but lowers the price target from $40 to $18.
The news of Barclays lowering the price target for Iovance Biotherapeutics from $40 to $18, despite maintaining an Overweight rating, could potentially lead to a negative sentiment among investors, possibly causing a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100